Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer

Mezvrishvili, Zaza; Managadze, L.

doi:10.1007/s11255-006-0038-x

Cited by 7 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study was carried out under strict ethical procedures recommended by the Ethics Committee of the University of Chile (August 17, 2010), and the Northern Metropolitan Health Service, National Cancer Institute (April 4, 2015), in accordance with the procedures suggested in the Declaration of Helsinki (Declaration of Helsinki, 1964), and according to Chilean Laws 20.120, 20.584, and 19.628, and the guidelines of the Good Clinical Practices. Chemotherapy regimen for all patients involved the administration of cisplatin and etoposide in combination with bleomycin for up to four cycles (BEP schedule), which is the standard treatment for patients with low or intermediate risk testicular cancers, all over the world (Pizzocaro et al, 1985; Mezvrishvili and Managadze, 2006).…”

Section: Methodsmentioning

confidence: 99%

“…Patients with intermediate-risk or high-risk disease are routinely treated with up to four cycles of BEP or four cycles of etoposide, ifosfamide, and cisplatin. Chemotherapy for rescuing the relapse of testicular cancers includes a standard dose of vinblastine, cisplatin and ifosfamide (Pizzocaro et al, 1985; Mezvrishvili and Managadze, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients

Lavanderos¹,

Cayún²,

Roco³

et al. 2019

Front. Pharmacol.

View full text Add to dashboard Cite

Testicular cancer is one of the most commonly occurring malignant tumors in young men with fourfold higher rate of incidence and threefold higher mortality rates in Chile than the average global rates. Surgery is the initial line of treatment for testicular cancers, and is generally followed by chemotherapy, usually with combinations of bleomycin, etoposide, and cisplatin (BEP). However, the adverse effects of chemotherapy vary significantly among individuals; therefore, the present study explored the association of functionally significant allelic variations in genes related to the pharmacokinetics/pharmacodynamics of BEP and DNA repair enzymes with chemotherapy-induced toxicity in BEP-treated testicular cancer patients. We prospectively recruited 119 patients diagnosed with testicular cancer from 2010 to 2017. Genetic polymorphisms were analyzed using PCR and/or qPCR with TaqMan®probes. Toxicity was evaluated based on the Common Terminology Criteria for Adverse Events, v4.03. After univariate analyses to define more relevant genetic variants (p < 0.2) and clinical conditions in relation to severe (III–IV) adverse drug reactions (ADRs), stepwise forward multivariate logistic regression analyses were performed. As expected, the main severe ADRs associated with the non-genetic variables were hematological (neutropenia and leukopenia). Univariate statistical analyses revealed that patients with ERCC2 rs13181 T/G and/or CYP3A4 rs2740574 A/G genotypes are more likely to develop alopecia; patients with ERCC2 rs238406 C/C genotype may develop leukopenia, and patients with GSTT1-null genotype could develop lymphocytopenia (III–IV). Patients with ERCC2 rs1799793 A/A were at risk of developing severe anemia. The BLMH rs1050565 G/G genotype was found to be associated with pain, and the GSTP1 G/G genotype was linked infection (p < 0.05). Multivariate analysis showed an association between specific ERCC1/2 genotypes and cumulative dose of BEP drugs with the appearance of severe leukopenia and/or febrile neutropenia. Grades III–IV vomiting, nausea, and alopecia could be partly explained by the presence of specific ERCC1/2, MDR1, GSTP1, and BLMH genotypes (p < 0.05). Hence, we provide evidence for the usefulness of pharmacogenetics as a tool for predicting severe ADRs in testicular cancer patients treated with BEP chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients

Lavanderos¹,

Cayún²,

Roco³

et al. 2019

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Both regimens are category 1 recommendations, and either is preferable to initial RPLND because these patients nearly always have disseminated disease. 82,83…”

Section: Primary Treatment Of Nonseminoma Stage Ismentioning

confidence: 99%

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Gilligan

Lin

Aggarwal

et al. 2019

Journal of the National Comprehensive Cancer Network

230

233

View full text Add to dashboard Cite

Testicular cancer is relatively uncommon and accounts for ,1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nervesparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with .50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.

show abstract

“…Etoposide is an anticancer drug used as a single-agent or as combination chemotherapy in the treatment of testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer [1][2][3][4][5]. Side effects of treatment include, vomiting, neutropenia, myelosuppression, and alopecia [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Melatonin Loading Chitosan-Tripolyphosphate Nanoparticles: Application in Attenuating Etoposide-Induced Genotoxicity in HepG2 Cells

Shokrzadeh

Ghassemi-Barghi²

2018

Pharmacology

View full text Add to dashboard Cite

Etoposide is one of the most effective chemotherapeutic agents used in the treatment of various types of cancers. However, as a Topoisomerase II inhibitor, during clinical use, several side effects may occur. In addition, in several in vivo and in vitro studies, etoposide has been shown to have a range of genotoxic effects including single and double strand breaks. Melatonin is an anti-aging and antioxidant hormone synthesized from the pineal gland. The genoprotective, antioxidant, and free radical scavenger properties of melatonin have been well explained in various studies. The aim of this study was to explore whether melatonin nanoparticles protects against etoposide-induced genotoxicity in the HepG2 cell line. HepG2 cells (25 × 10⁴ cells/well) were cultured in 24-well plates: a control group and 3 melatonin and its nanoparticles + etoposide groups (pre- and cotreatment conditions). Our results show that etoposide induced a noticeable genotoxic effect in HepG2 cells. Melatonin reduced the effects of etoposide significantly in both types of experiment conditions, through the reduction of the level of DNA damage measured via comet assay. Furthermore, melatonin decreased the intracellular reactive oxygen species generation. It also increased the intracellular glutathione levels in HepG2 cells. Nano melatonin is more effective than regular melatonin. The most protective effect was observed with melatonin when it was administrated 24 h before etoposide treatment.

show abstract

Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer

Cited by 7 publications

References 15 publications

Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients

Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Melatonin Loading Chitosan-Tripolyphosphate Nanoparticles: Application in Attenuating Etoposide-Induced Genotoxicity in HepG2 Cells

Contact Info

Product

Resources

About